Patel, K. K., Larson, S. M., Nadeem, O., Munshi, N. C., Iida, S., Mailankody, S., Neri, P., Gregory, T., Piasecki, J. C., Ziyad, S., Hu, H., Groeneveld, S., Johnston, S., Pulham, T., Wong, S., Davis, J., Bal, S., Kumar, A., Freeman, C. L. (2025). QUINTESSENTIAL: A multicenter phase 2 study evaluating the efficacy and safety of arlocabtagene autoleucel (arlo-cel) in triple- and quad-class exposed patients with relapsed or refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps7563